MSM 735
Alternative Names: MSM-735Latest Information Update: 06 Sep 2023
At a glance
- Originator MSM Protein Technologies
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Idiopathic pulmonary fibrosis; Multiple sclerosis; Solid tumours
Most Recent Events
- 06 Sep 2023 MSM 735 is still in preclinical trials for Solid tumours (Metastatic disease), Haematological malignancies, Idiopathic pulmonary fibrosis and Multiple sclerosis in USA (MSM Protein Technologies pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA